AstraZeneca drug cocktail succeeds in late-stage research to deal with COVID-19 By Reuters


© Reuters. FILE PHOTO: AstraZeneca logo will be seen outside its North America headquarters in Wilmington, Delaware, USA on March 22, 2021. REUTERS / Rachel Wisniewski


(Reuters) – AstraZeneca’s experimental COVID-19 antibody drug cocktail was able to reduce serious illness or death in non-hospitalized patients in a late stage, the British drug maker said on Monday.

The drug, named AZD7442, reduced the risk of severe COVID-19 illness or death by 50% in patients who were symptomatic for seven days or less, thereby meeting the study’s main objective.

“Early intervention with our antibody can significantly reduce the progression of a serious disease and protect it for more than six months,” said Mene Pangalos, Executive Vice President, Biopharmaceuticals R&D at AstraZeneca (NASDAQ :).

The company will discuss the data with health officials, it added, without going into detail.

AstraZeneca is also developing the drug cocktail as a therapy to protect people who do not have a sufficiently strong immune response to COVID-19 vaccines. It applied for emergency clearance from U.S. regulators last week for use as a preventive drug.

Disclaimer: Fusion Media would like to remind you that the information contained on this website is not necessarily real-time or accurate. All CFDs (stocks, indices, futures) and forex prices are not provided by exchanges, but by market makers. Therefore, prices may not be accurate and may differ from the actual market price, meaning that prices are indicative and not suitable for trading purposes. Therefore, Fusion Media is not responsible for any trading losses you may incur as a result of using this information.

Fusion Media or any other person involved in Fusion Media assumes no liability for any loss or damage that might arise from reliance on the information contained on this website, including data, prices, charts and buy / sell signals. Please inform yourself comprehensively about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment.

You might also like

Leave A Reply

Your email address will not be published.